Cytek Biosciences, Inc.
CTKB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | 0.05 | 0.02 | -1.77 |
| FCF Yield | -0.34% | -0.19% | 0.13% | 1.71% |
| EV / EBITDA | -34.85 | -53.79 | 106.33 | 185.69 |
| Quality | ||||
| ROIC | -2.08% | -3.59% | 0.63% | -5.94% |
| Gross Margin | 52.34% | 48.62% | 58.55% | 56.32% |
| Cash Conversion Ratio | 0.71 | -0.02 | 0.01 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.44% | 3.74% | 5.87% | 6.91% |
| Free Cash Flow Growth | -50.82% | -189.03% | -91.19% | 148.11% |
| Safety | ||||
| Net Debt / EBITDA | 5.77 | 9.81 | -11.48 | -49.72 |
| Interest Coverage | -25.66 | -51.46 | 0.00 | -35.70 |
| Efficiency | ||||
| Inventory Turnover | 0.44 | 0.47 | 0.54 | 0.48 |
| Cash Conversion Cycle | 287.52 | 285.06 | 239.80 | 257.66 |